| Year |
Citation |
Score |
| 2023 |
Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic - a new approach to cancer therapy. Nature Reviews. Clinical Oncology. PMID 36781982 DOI: 10.1038/s41571-023-00736-3 |
0.349 |
|
| 2023 |
Raina K, Forbes CD, Stronk R, Rappi JP, Eastman KJ, Gerritz SW, Yu X, Li H, Bhardwaj A, Forgione M, Hundt A, King MP, Posner ZM, Denny A, McGovern A, ... ... Crews CM, et al. Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively. Biorxiv : the Preprint Server For Biology. PMID 36711980 DOI: 10.1101/2023.01.01.522436 |
0.78 |
|
| 2022 |
Swartzel JC, Bond MJ, Pintado-Urbanc AP, Daftary M, Krone MW, Douglas T, Carder EJ, Zimmer JT, Maeda T, Simon MD, Crews CM. Targeted Degradation of mRNA Decapping Enzyme DcpS by a VHL-Recruiting PROTAC. Acs Chemical Biology. PMID 35749470 DOI: 10.1021/acschembio.2c00145 |
0.808 |
|
| 2022 |
Li K, Crews CM. PROTACs: past, present and future. Chemical Society Reviews. PMID 35671157 DOI: 10.1039/d2cs00193d |
0.343 |
|
| 2022 |
Nalawansha DA, Li K, Hines J, Crews CM. Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation. Journal of the American Chemical Society. 144: 5594-5605. PMID 35311258 DOI: 10.1021/jacs.2c00874 |
0.332 |
|
| 2022 |
Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nature Reviews. Drug Discovery. PMID 35042991 DOI: 10.1038/s41573-021-00371-6 |
0.337 |
|
| 2021 |
Chen PH, Hu Z, An E, Okeke I, Zheng S, Luo X, Gong A, Jaime-Figueroa S, Crews CM. Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs). Acs Chemical Biology. PMID 34780684 DOI: 10.1021/acschembio.1c00693 |
0.352 |
|
| 2021 |
Crews CM, Hu Z. Recent Developments in PROTAC-mediated Protein Degradation: From Bench to Clinic. Chembiochem : a European Journal of Chemical Biology. PMID 34494353 DOI: 10.1002/cbic.202100270 |
0.352 |
|
| 2021 |
Bond MJ, Crews CM. Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. Rsc Chemical Biology. 2: 725-742. PMID 34212149 DOI: 10.1039/d1cb00011j |
0.352 |
|
| 2021 |
Samarasinghe KTG, Crews CM. Targeted protein degradation: a promise for undruggable proteins. Cell Chemical Biology. PMID 34004187 DOI: 10.1016/j.chembiol.2021.04.011 |
0.366 |
|
| 2021 |
Alabi SB, Crews CM. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. The Journal of Biological Chemistry. 296: 100647. PMID 33839157 DOI: 10.1016/j.jbc.2021.100647 |
0.365 |
|
| 2020 |
Bond MJ, Chu L, Nalawansha DA, Li K, Crews CM. Targeted Degradation of Oncogenic KRAS by VHL-Recruiting PROTACs. Acs Central Science. 6: 1367-1375. PMID 32875077 DOI: 10.1021/Acscentsci.0C00411 |
0.42 |
|
| 2020 |
Nalawansha DA, Crews CM. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chemical Biology. 27: 998-1014. PMID 32795419 DOI: 10.1016/J.Chembiol.2020.07.020 |
0.427 |
|
| 2020 |
Burslem GM, Bondeson DP, Crews CM. Scaffold hopping enables direct access to more potent PROTACs with in vivo activity. Chemical Communications (Cambridge, England). 56: 6890-6892. PMID 32519703 DOI: 10.1039/D0Cc02201B |
0.338 |
|
| 2020 |
Flowers GP, Crews CM. Remembering where we are: Positional information in salamander limb regeneration. Developmental Dynamics : An Official Publication of the American Association of Anatomists. PMID 32124513 DOI: 10.1002/Dvdy.167 |
0.524 |
|
| 2020 |
Nalawansha DA, Paiva SL, Rafizadeh DN, Pettersson M, Qin L, Crews CM. Retraction of "Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs)". Acs Central Science. 6: 312. PMID 32123750 DOI: 10.1021/Acscentsci.0C00021 |
0.394 |
|
| 2020 |
Saenz D, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury J, ... ... Crews CM, et al. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. Blood. PMID 32068780 DOI: 10.1182/Blood.2019002922 |
0.33 |
|
| 2020 |
Sanor LD, Flowers GP, Crews CM. Generation of Chimeric Axolotls with Mutant Haploid Limbs Through Embryonic Grafting. Journal of Visualized Experiments : Jove. PMID 32065121 DOI: 10.3791/60156 |
0.543 |
|
| 2020 |
Sanor LD, Flowers GP, Crews CM. Multiplex CRISPR/Cas screen in regenerating haploid limbs of chimeric Axolotls. Elife. 9. PMID 31989926 DOI: 10.7554/Elife.48511 |
0.55 |
|
| 2020 |
Burslem GM, Crews CM. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell. PMID 31955850 DOI: 10.1016/J.Cell.2019.11.031 |
0.393 |
|
| 2020 |
Jaime-Figueroa S, Buhimschi AD, Toure M, Hines J, Crews CM. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. Bioorganic & Medicinal Chemistry Letters. 30: 126877. PMID 31879210 DOI: 10.1016/J.Bmcl.2019.126877 |
0.646 |
|
| 2019 |
Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nature Reviews. Drug Discovery. PMID 31666732 DOI: 10.1038/S41573-019-0047-Y |
0.457 |
|
| 2019 |
Pfaff P, Samarasinghe KTG, Crews CM, Carreira EM. Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs. Acs Central Science. 5: 1682-1690. PMID 31660436 DOI: 10.1021/Acscentsci.9B00713 |
0.448 |
|
| 2019 |
Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation. Cancer Research. PMID 31311809 DOI: 10.1158/0008-5472.Can-19-1236 |
0.441 |
|
| 2019 |
Nalawansha DA, Paiva SL, Rafizadeh DN, Pettersson M, Qin L, Crews CM. Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs). Acs Central Science. 5: 1079-1084. PMID 31263767 DOI: 10.1021/Acscentsci.9B00224 |
0.481 |
|
| 2019 |
Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future. Drug Discovery Today. Technologies. 31: 15-27. PMID 31200855 DOI: 10.1016/J.Ddtec.2019.01.002 |
0.436 |
|
| 2019 |
Hellerschmied D, Serebrenik YV, Shao L, Burslem GM, Crews CM. Protein Folding State-dependent Sorting at the Golgi Apparatus. Molecular Biology of the Cell. mbcE19010069. PMID 31166830 DOI: 10.1091/Mbc.E19-01-0069 |
0.796 |
|
| 2019 |
Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, ... ... Crews CM, et al. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. PMID 31023702 DOI: 10.1182/Blood.2018893982 |
0.743 |
|
| 2019 |
Paiva SL, Crews CM. Targeted protein degradation: elements of PROTAC design. Current Opinion in Chemical Biology. 50: 111-119. PMID 31004963 DOI: 10.1016/J.Cbpa.2019.02.022 |
0.469 |
|
| 2019 |
Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleava M, Ishizawa J, You MJ, Kantarjian H, et al. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. The Journal of Clinical Investigation. 130. PMID 30829648 DOI: 10.1172/Jci120654 |
0.353 |
|
| 2019 |
Buhimschi AD, Crews CM. Evolving Rules for Protein Degradation? Insights from the Zinc Finger Degrome. Biochemistry. PMID 30681837 DOI: 10.1021/Acs.Biochem.8B01307 |
0.368 |
|
| 2019 |
Smith BE, Wang SL, Jaime-Figueroa S, Harbin A, Wang J, Hamman BD, Crews CM. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nature Communications. 10: 131. PMID 30631068 DOI: 10.1038/S41467-018-08027-7 |
0.416 |
|
| 2019 |
Neklesa T, Snyder LB, Willard RR, Vitale N, Pizzano J, Gordon DA, Bookbinder M, Macaluso J, Dong H, Ferraro C, Wang G, Wang J, Crews CM, Houston J, Crew AP, et al. ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer. Journal of Clinical Oncology. 37: 259-259. DOI: 10.1200/Jco.2019.37.7_Suppl.259 |
0.367 |
|
| 2019 |
Flanagan J, Qian Y, Gough S, Andreoli M, Bookbinder M, Cadelina G, Bradley J, Rousseau E, Willard R, Pizzano J, Crews C, Crew A, Taylor I, Houston J. Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P5-04-18 |
0.344 |
|
| 2019 |
Cacace AM, Chandler J, Flanagan JJ, Berlin M, Cadelina G, Pizzano J, Bookbinder M, Crews CM, Crew AP, Taylor I, Houston J. A New Therapeutic Strategy For Tauopathies: Discovery Of Highly Potent Brain Penetrant Protactm Degrader Molecules That Target Pathologic Tau Protein Species Alzheimers & Dementia. 15: 1624. DOI: 10.1016/J.Jalz.2019.06.4856 |
0.381 |
|
| 2018 |
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, ... ... Crews CM, et al. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. PMID 30575820 DOI: 10.1038/S41375-018-0334-3 |
0.726 |
|
| 2018 |
Cromm PM, Samarasinghe K, Hines J, Crews CM. Addressing Kinase-Independent Functions of Fak via PROTAC-mediated Degradation. Journal of the American Chemical Society. PMID 30444612 DOI: 10.1021/Jacs.8B08008 |
0.439 |
|
| 2018 |
Burslem GM, Song J, Chen X, Hines J, Crews CM. Enhancing Anti-Proliferative Activity and Selectivity of a FLT-3 Inhibitor by PROTAC Conversion. Journal of the American Chemical Society. PMID 30427680 DOI: 10.1021/Jacs.8B10320 |
0.413 |
|
| 2018 |
Hines J, Lartigue S, Dong H, Qian Y, Crews CM. MDM2-recruiting PROTAC Offers Superior, Synergistic Anti-proliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. Cancer Research. PMID 30385614 DOI: 10.1158/0008-5472.Can-18-2918 |
0.453 |
|
| 2018 |
Burslem GM, Ottis P, Jaime-Figueroa S, Morgan A, Cromm P, Toure M, Crews C. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure Degradation Relationships. Chemmedchem. PMID 29870139 DOI: 10.1002/Cmdc.201800271 |
0.814 |
|
| 2018 |
Serebrenik YV, Hellerschmied D, Toure M, López-Giráldez F, Brookner D, Crews CM. Targeted protein unfolding uncovers a Golgi-specific transcriptional stress response. Molecular Biology of the Cell. 29: 1284-1298. PMID 29851555 DOI: 10.1091/Mbc.E17-11-0693 |
0.807 |
|
| 2018 |
Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, Woyach JA, Johnson AJ, Byrd JC, Crews CM. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase using PROTAC-mediated Degradation. Biochemistry. PMID 29851337 DOI: 10.1021/Acs.Biochem.8B00391 |
0.623 |
|
| 2018 |
Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, et al. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. PMID 29581547 DOI: 10.1038/S41375-018-0044-X |
0.785 |
|
| 2018 |
Flowers GP, Crews CM. Regeneration writ large. Nature. 554: 34-35. PMID 29388980 DOI: 10.1038/d41586-017-09008-4 |
0.45 |
|
| 2018 |
Flanagan J, Qian Y, Gough S, Andreoli M, Bookbinder M, Bradley J, Rousseau E, Willard R, Crews C, Crew A, Taylor I, Houston J. Abstract P4-04-04: Identification and development of oral estrogen receptor PROTAC degraders for breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-04-04 |
0.361 |
|
| 2018 |
Neklesa T, Snyder LB, Willard RR, Vitale N, Raina K, Pizzano J, Gordon D, Bookbinder M, Macaluso J, Dong H, Liu Z, Ferraro C, Wang G, Wang J, Crews CM, et al. Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer Cancer Research. 78: 5236-5236. DOI: 10.1158/1538-7445.Am2018-5236 |
0.726 |
|
| 2018 |
Coleman KG, Crews CM. Proteolysis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins Annual Review of Cancer Biology. 2: 41-58. DOI: 10.1146/annurev-cancerbio-030617-050430 |
0.329 |
|
| 2017 |
Bondeson DP, Smith BE, Burslem GM, Buhimschi AD, Hines J, Jaime-Figueroa S, Wang J, Hamman BD, Ishchenko A, Crews CM. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chemical Biology. PMID 29129718 DOI: 10.1016/J.Chembiol.2017.09.010 |
0.501 |
|
| 2017 |
Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, Toure M, Dong H, Qian Y, Wang J, Crew AP, Hines J, Crews CM. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chemical Biology. PMID 29129716 DOI: 10.1016/J.Chembiol.2017.09.009 |
0.688 |
|
| 2017 |
Flowers GP, Sanor LD, Crews CM. Lineage tracing of genome-edited alleles reveals high fidelity axolotl limb regeneration. Elife. 6. PMID 28917058 DOI: 10.7554/Elife.25726 |
0.544 |
|
| 2017 |
Cromm PM, Crews CM. The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target. Acs Central Science. 3: 830-838. PMID 28852696 DOI: 10.1021/Acscentsci.7B00252 |
0.392 |
|
| 2017 |
Burslem GM, Crews CM. Small-Molecule Modulation of Protein Homeostasis. Chemical Reviews. PMID 28777566 DOI: 10.1021/Acs.Chemrev.7B00077 |
0.37 |
|
| 2017 |
Ottis P, Toure M, Cromm PM, Ko E, Gustafson JL, Crews CM. Assessing Different E3 Ligases for Small Molecule-induced Protein Ubiquitination and Degradation. Acs Chemical Biology. PMID 28767222 DOI: 10.1021/Acschembio.7B00485 |
0.812 |
|
| 2017 |
Crew AP, Raina K, Dong H, Qian Y, Wang J, Vigil D, Serebrenik YV, Hamman BD, Morgan A, Ferraro C, Siu K, Neklesa TK, Winkler JD, Coleman KG, Crews CM. Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. Journal of Medicinal Chemistry. PMID 28692295 DOI: 10.1021/Acs.Jmedchem.7B00635 |
0.78 |
|
| 2017 |
Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, ... ... Crews CM, et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. PMID 28663582 DOI: 10.1038/Leu.2017.207 |
0.779 |
|
| 2017 |
Cromm PM, Crews CM. Targeted Protein Degradation: from Chemical Biology to Drug Discovery. Cell Chemical Biology. PMID 28648379 DOI: 10.1016/J.Chembiol.2017.05.024 |
0.471 |
|
| 2017 |
Raina K, Crews CM. Targeted protein knockdown using small molecule degraders. Current Opinion in Chemical Biology. 39: 46-53. PMID 28605671 DOI: 10.1016/J.Cbpa.2017.05.016 |
0.791 |
|
| 2017 |
Salami J, Crews CM. Waste disposal-An attractive strategy for cancer therapy. Science (New York, N.Y.). 355: 1163-1167. PMID 28302825 DOI: 10.1126/Science.Aam7340 |
0.434 |
|
| 2017 |
Ottis P, Crews CM. PROTACs: Induced Protein Degradation as a Therapeutic Strategy. Acs Chemical Biology. PMID 28263557 DOI: 10.1021/Acschembio.6B01068 |
0.823 |
|
| 2017 |
Neklesa TK, Winkler JD, Crews CM. Targeted Protein Degradation by PROTACs. Pharmacology & Therapeutics. PMID 28223226 DOI: 10.1016/J.Pharmthera.2017.02.027 |
0.498 |
|
| 2017 |
Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, ... ... Crews CM, et al. Novel BET protein proteolysis targeting chimera (BET-PROTAC) exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Leukemia. PMID 28042144 DOI: 10.1038/Leu.2016.393 |
0.772 |
|
| 2017 |
Neklesa TK, Snyder LB, Bookbinder M, Chen X, Crew AP, Crews CM, Dong H, Gordon DA, Raina K, Rossi AK, Taylor I, Vitale N, Wang J, Willard RR, Zimmermann K. An oral androgen receptor PROTAC degrader for prostate cancer. Journal of Clinical Oncology. 35: 273-273. DOI: 10.1200/Jco.2017.35.6_Suppl.273 |
0.743 |
|
| 2017 |
Sun B, Fiskus W, Raina K, Qian Y, Crew A, Saenz DT, Mill CP, Nowak AJ, Saenz DN, Crews CM, Bhalla KN. Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells Blood. 130: 1265-1265. DOI: 10.1182/Blood.V130.Suppl_1.1265.1265 |
0.776 |
|
| 2017 |
Flanagan J, Rossi A, Anderoli M, Willard R, Gordon D, Harling J, Churcher I, Smith I, Zinn N, Bantscheff M, Crews C, Crew A, Coleman K, Winkler J, Qian Y. Abstract S4-03: Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S4-03 |
0.383 |
|
| 2017 |
Neklesa TK, Snyder LB, Bookbinder M, Chen X, Crew AP, Crews CM, Dong H, Gordon D, Macaluso J, Raina K, Rossi A, Taylor I, Vitale N, Wang J, Willard RR, et al. Abstract 5637: An oral Androgen Receptor PROTAC degrader for prostate cancer Cancer Research. 77: 5637-5637. DOI: 10.1158/1538-7445.Am2017-5637 |
0.732 |
|
| 2017 |
Saenz DT, Fiskus WC, Raina K, Manshouri T, Coleman KG, Qian Y, Crew AP, Shen A, Mill CP, Sun B, Kim M, Nowak AJ, Verstovsek S, Crews CM, Bhalla KN. Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells Cancer Research. 77: 5067-5067. DOI: 10.1158/1538-7445.Am2017-5067 |
0.747 |
|
| 2016 |
Toure M, Jaime-Figueroa S, Burslem GM, Crews CM. Expeditious Synthesis of Isoquinolones and Isocoumarins with a Vinyl Borane as an Acetylene Equivalent. European Journal of Organic Chemistry. 2016: 4171-4175. PMID 28781577 DOI: 10.1002/Ejoc.201600575 |
0.571 |
|
| 2016 |
Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nature Reviews. Drug Discovery. PMID 27885283 DOI: 10.1038/Nrd.2016.211 |
0.467 |
|
| 2016 |
Bondeson DP, Crews CM. Targeted Protein Degradation by Small Molecules. Annual Review of Pharmacology and Toxicology. PMID 27732798 DOI: 10.1146/Annurev-Pharmtox-010715-103507 |
0.443 |
|
| 2016 |
Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, Wang J, Chen X, Dong H, Siu K, Winkler JD, Crew AP, Crews CM, Coleman KG. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 27274052 DOI: 10.1073/Pnas.1521738113 |
0.743 |
|
| 2016 |
Crews CM, Georg G, Wang S. Inducing Protein Degradation as a Therapeutic Strategy. Journal of Medicinal Chemistry. PMID 27199030 DOI: 10.1021/Acs.Jmedchem.6B00735 |
0.412 |
|
| 2016 |
Al-Obaidi N, Mitchison TJ, Crews CM, Mayer TU. Identification of MAC1: A Small Molecule That Rescues Spindle Bipolarity in Monastrol-Treated Cells. Acs Chemical Biology. PMID 27121275 DOI: 10.1021/Acschembio.6B00203 |
0.346 |
|
| 2016 |
Kostic M, Crews CM, Hertweck C, Shokat K, Suga H. Our Advisors, Our Ambassadors, Our Editorial Board Members. Cell Chemical Biology. 23: 311-2. PMID 26991096 DOI: 10.1016/J.Chembiol.2016.03.004 |
0.318 |
|
| 2016 |
Kostic M, Crews CM, Hertweck C, Shokat K, Suga H. Cell Chemical Biology: Home of Exciting Chemical Biology. Cell Chemical Biology. 23: 1-2. PMID 26933730 DOI: 10.1016/J.Chembiol.2016.01.001 |
0.429 |
|
| 2016 |
Toure M, Crews CM. Small-Molecule PROTACS: New Approaches to Protein Degradation. Angewandte Chemie (International Ed. in English). PMID 26756721 DOI: 10.1002/Anie.201507978 |
0.698 |
|
| 2016 |
Piya S, Bhattacharya S, Mu H, Lorenzi PL, McQueen T, Davis ER, Ruvolo V, Baran N, Qian Y, Crews C, Kantarjian HM, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects Blood. 128: 748-748. DOI: 10.1182/Blood.V128.22.748.748 |
0.415 |
|
| 2016 |
Saenz DT, Fiskus W, Raina K, Manshouri T, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Mill CP, Sun B, Verstovsek S, Crews C, Bhalla KN. Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells Blood. 128: 747-747. DOI: 10.1182/Blood.V128.22.747.747 |
0.746 |
|
| 2016 |
Sun B, Fiskus W, Zhang L, Raina K, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Saenz DT, Mill CP, Wang M, Crews C, Bhalla KN. Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells Blood. 128: 1058-1058. DOI: 10.1182/Blood.V128.22.1058.1058 |
0.765 |
|
| 2016 |
Raina K, Lu J, Qian Y, Altieri M, Dong H, Wang J, Chen X, Crew A, Coleman K, Crews C, Winkler J. Abstract 4710: BRD4 degradation by PROTACs represents a more effective therapeutic strategy than BRD4 inhibitors in ovarian cancer Cancer Research. 76: 4710-4710. DOI: 10.1158/1538-7445.Am2016-4710 |
0.768 |
|
| 2016 |
Toure M, Crews CM. Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen Angewandte Chemie. 128: 2002-2010. DOI: 10.1002/Ange.201507978 |
0.625 |
|
| 2015 |
Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, Hines J, Crews CM. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angewandte Chemie (International Ed. in English). PMID 26593377 DOI: 10.1002/Anie.201507634 |
0.818 |
|
| 2015 |
Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS. Development of small molecules targeting the pseudokinase Her3. Bioorganic & Medicinal Chemistry Letters. 25: 3382-9. PMID 26094118 DOI: 10.1016/J.Bmcl.2015.04.103 |
0.358 |
|
| 2015 |
Gustafson JL, Neklesa TK, Cox CS, Roth AG, Buckley DL, Tae HS, Sundberg TB, Stagg DB, Hines J, McDonnell DP, Norris JD, Crews CM. Small-Molecule-Mediated Degradation of the Androgen Receptor Through Hydrophobic Tagging. Angewandte Chemie (International Ed. in English). PMID 26083457 DOI: 10.1002/Anie.201503720 |
0.608 |
|
| 2015 |
Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N, Grandi P, Shimamura S, Bergamini G, Faelth-Savitski M, ... ... Crews CM, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology. 11: 611-7. PMID 26075522 DOI: 10.1038/Nchembio.1858 |
0.699 |
|
| 2015 |
Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Smith IE, Miah AH, Harling JD, Crews CM. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. Acs Chemical Biology. PMID 26070106 DOI: 10.1021/Acschembio.5B00442 |
0.829 |
|
| 2015 |
Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Hines J, Winkler JD, Crew AP, Coleman K, Crews CM. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chemistry & Biology. 22: 755-63. PMID 26051217 DOI: 10.1016/J.Chembiol.2015.05.009 |
0.785 |
|
| 2015 |
Flowers GP, Crews CM. Generating and identifying axolotls with targeted mutations using Cas9 RNA-guided nuclease. Methods in Molecular Biology (Clifton, N.J.). 1290: 279-95. PMID 25740494 DOI: 10.1007/978-1-4939-2495-0_22 |
0.572 |
|
| 2015 |
Coleman K, Lu J, Qian Y, Altieri M, Raina K, Dong H, Wang J, Hines J, Crew AP, Crews CM. BRD4 degraders produce long-lasting loss of BRD4 Ppotein and robust efficacy in Burkitt’s lymphoma cells. Journal of Clinical Oncology. 33: 8557-8557. DOI: 10.1200/Jco.2015.33.15_Suppl.8557 |
0.753 |
|
| 2015 |
Lu J, Qian Y, Raina K, Altieri M, Dong H, Wang J, Chen X, Crew A, Coleman K, Crews C, Winkler J. BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL Blood. 126: 2050-2050. DOI: 10.1182/Blood.V126.23.2050.2050 |
0.768 |
|
| 2015 |
Jin M, Winkler JD, Coleman K, Crew AP, Rossi AK, Willard RR, Dong H, Siu K, Wang J, Gordon DA, Chen X, Ferraro C, Crews CM, Neklesa TK. Abstract LB-097: Targeted degradation of the androgen receptor in prostate cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-097 |
0.391 |
|
| 2015 |
Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Winkler J, Crew A, Coleman K, Hines J, Crews C. Abstract LB-010: Hijacking the E3 ubiquitin ligase cereblon to create efficient BRD4 degraders Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-010 |
0.719 |
|
| 2015 |
Winkler JD, Jin M, Crew AP, Rossi AK, Willard RR, Dong H, Siu K, Wang J, Gordon DA, Chen X, Ferraro C, Crews CM, Coleman K, Neklesa TK. Abstract PR08: ARV-330: An androgen receptor PROTAC degrader for prostate cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Pr08 |
0.326 |
|
| 2015 |
Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, Hines J, Crews CM. Modulares PROTAC-Design zum Abbau von onkogenem BCR-ABL Angewandte Chemie. 128: 818-821. DOI: 10.1002/Ange.201507634 |
0.571 |
|
| 2014 |
Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS. Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology. 10: 1006-12. PMID 25326665 DOI: 10.1038/Nchembio.1658 |
0.391 |
|
| 2014 |
Raina K, Noblin DJ, Serebrenik YV, Adams A, Zhao C, Crews CM. Targeted protein destabilization reveals an estrogen-mediated ER stress response. Nature Chemical Biology. 10: 957-62. PMID 25242550 DOI: 10.1038/Nchembio.1638 |
0.789 |
|
| 2014 |
Flowers GP, Timberlake AT, McLean KC, Monaghan JR, Crews CM. Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided nuclease. Development (Cambridge, England). 141: 2165-71. PMID 24764077 DOI: 10.1242/Dev.105072 |
0.579 |
|
| 2014 |
Buckley DL, Crews CM. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angewandte Chemie (International Ed. in English). 53: 2312-30. PMID 24459094 DOI: 10.1002/Anie.201307761 |
0.696 |
|
| 2014 |
Buckley DL, Crews CM. Steuerung der intrazellulären Proteinmenge durch niedermolekulare Modulatoren des Ubiquitin-Proteasom-Systems Angewandte Chemie. 126: 2344-2363. DOI: 10.1002/Ange.201307761 |
0.558 |
|
| 2013 |
Neklesa TK, Noblin DJ, Kuzin A, Lew S, Seetharaman J, Acton TB, Kornhaber G, Xiao R, Montelione GT, Tong L, Crews CM. A bidirectional system for the dynamic small molecule control of intracellular fusion proteins. Acs Chemical Biology. 8: 2293-300. PMID 23978068 DOI: 10.1021/Cb400569K |
0.816 |
|
| 2013 |
Hines J, Gough JD, Corson TW, Crews CM. Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs. Proceedings of the National Academy of Sciences of the United States of America. 110: 8942-7. PMID 23674677 DOI: 10.1073/Pnas.1217206110 |
0.656 |
|
| 2013 |
Kim KB, Crews CM. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Natural Product Reports. 30: 600-4. PMID 23575525 DOI: 10.1039/C3Np20126K |
0.336 |
|
| 2012 |
Van Molle I, Thomann A, Buckley DL, So EC, Lang S, Crews CM, Ciulli A. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. Chemistry & Biology. 19: 1300-12. PMID 23102223 DOI: 10.1016/J.Chembiol.2012.08.015 |
0.753 |
|
| 2012 |
Buckley DL, Gustafson JL, Van Molle I, Roth AG, Tae HS, Gareiss PC, Jorgensen WL, Ciulli A, Crews CM. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. Angewandte Chemie (International Ed. in English). 51: 11463-7. PMID 23065727 DOI: 10.1002/Anie.201206231 |
0.764 |
|
| 2012 |
Holman EC, Campbell LJ, Hines J, Crews CM. Microarray analysis of microRNA expression during axolotl limb regeneration. Plos One. 7: e41804. PMID 23028429 DOI: 10.1371/Journal.Pone.0041804 |
0.558 |
|
| 2012 |
Noblin DJ, Page CM, Tae HS, Gareiss PC, Schneekloth JS, Crews CM. A HaloTag-based small molecule microarray screening methodology with increased sensitivity and multiplex capabilities. Acs Chemical Biology. 7: 2055-63. PMID 23013033 DOI: 10.1021/Cb300453K |
0.792 |
|
| 2012 |
Neklesa TK, Crews CM. Chemical biology: Greasy tags for protein removal. Nature. 487: 308-9. PMID 22810693 DOI: 10.1038/487308A |
0.42 |
|
| 2012 |
Buckley DL, Van Molle I, Gareiss PC, Tae HS, Michel J, Noblin DJ, Jorgensen WL, Ciulli A, Crews CM. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. Journal of the American Chemical Society. 134: 4465-8. PMID 22369643 DOI: 10.1021/Ja209924V |
0.821 |
|
| 2012 |
Tae HS, Sundberg TB, Neklesa TK, Noblin DJ, Gustafson JL, Roth AG, Raina K, Crews CM. Identification of hydrophobic tags for the degradation of stabilized proteins. Chembiochem : a European Journal of Chemical Biology. 13: 538-41. PMID 22271667 DOI: 10.1002/Cbic.201100793 |
0.804 |
|
| 2012 |
Buckley DL, Gustafson JL, Van Molle I, Roth AG, Tae HS, Gareiss PC, Jorgensen WL, Ciulli A, Crews CM. Niedermolekulare Inhibitoren der Wechselwirkung zwischen der E3-Ligase VHL und HIF1α Angewandte Chemie. 124: 11630-11634. DOI: 10.1002/Ange.201206231 |
0.681 |
|
| 2011 |
Sundberg TB, Darricarrere N, Cirone P, Li X, McDonald L, Mei X, Westlake CJ, Slusarski DC, Beynon RJ, Crews CM. Disruption of Wnt planar cell polarity signaling by aberrant accumulation of the MetAP-2 substrate Rab37. Chemistry & Biology. 18: 1300-11. PMID 22035799 DOI: 10.1016/J.Chembiol.2011.07.020 |
0.367 |
|
| 2011 |
Neklesa TK, Tae HS, Schneekloth AR, Stulberg MJ, Corson TW, Sundberg TB, Raina K, Holley SA, Crews CM. Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nature Chemical Biology. 7: 538-43. PMID 21725302 DOI: 10.1038/Nchembio.597 |
0.807 |
|
| 2011 |
Corson TW, Cavga H, Aberle N, Crews CM. Triptolide directly inhibits dCTP pyrophosphatase. Chembiochem : a European Journal of Chemical Biology. 12: 1767-73. PMID 21671327 DOI: 10.1002/Cbic.201100007 |
0.699 |
|
| 2011 |
Campbell LJ, Suárez-Castillo EC, Ortiz-Zuazaga H, Knapp D, Tanaka EM, Crews CM. Gene expression profile of the regeneration epithelium during axolotl limb regeneration. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 240: 1826-40. PMID 21648017 DOI: 10.1002/Dvdy.22669 |
0.551 |
|
| 2011 |
Schneekloth JS, Crews CM. Natural product inhibitors of the ubiquitin-proteasome pathway. Current Drug Targets. 12: 1581-94. PMID 21561423 DOI: 10.2174/138945011798109491 |
0.676 |
|
| 2011 |
Tae HS, Hines J, Schneekloth AR, Crews CM. Unexpected stereochemical tolerance for the biological activity of tyroscherin. Bioorganic & Medicinal Chemistry. 19: 1708-13. PMID 21315614 DOI: 10.1016/J.Bmc.2011.01.027 |
0.776 |
|
| 2011 |
Buckley DL, Corson TW, Aberle N, Crews CM. HIV protease-mediated activation of sterically capped proteasome inhibitors and substrates. Journal of the American Chemical Society. 133: 698-700. PMID 21186803 DOI: 10.1021/Ja109377P |
0.73 |
|
| 2010 |
Tae HS, Hines J, Schneekloth AR, Crews CM. Total synthesis and biological evaluation of tyroscherin. Organic Letters. 12: 4308-11. PMID 20831175 DOI: 10.1021/Ol101801U |
0.771 |
|
| 2010 |
Crews CM. Targeting the undruggable proteome: the small molecules of my dreams. Chemistry & Biology. 17: 551-5. PMID 20609404 DOI: 10.1016/J.Chembiol.2010.05.011 |
0.365 |
|
| 2010 |
Hines J, Ju R, Dutschman GE, Cheng YC, Crews CM. Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides. The Journal of Pharmacology and Experimental Therapeutics. 334: 729-38. PMID 20571059 DOI: 10.1124/Jpet.110.169110 |
0.356 |
|
| 2010 |
Ju R, Cirone P, Lin S, Griesbach H, Slusarski DC, Crews CM. Activation of the planar cell polarity formin DAAM1 leads to inhibition of endothelial cell proliferation, migration, and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 107: 6906-11. PMID 20351293 DOI: 10.1073/Pnas.1001075107 |
0.318 |
|
| 2010 |
Raina K, Crews CM. Chemical inducers of targeted protein degradation. The Journal of Biological Chemistry. 285: 11057-60. PMID 20147751 DOI: 10.1074/Jbc.R109.078105 |
0.779 |
|
| 2010 |
Gareiss PC, Schneekloth AR, Salcius MJ, Seo SY, Crews CM. Identification and characterization of a peptidic ligand for Ras. Chembiochem : a European Journal of Chemical Biology. 11: 517-22. PMID 20082398 DOI: 10.1002/Cbic.200900547 |
0.757 |
|
| 2009 |
Custar DW, Zabawa TP, Hines J, Crews CM, Scheidt KA. Total synthesis and structure-activity investigation of the marine natural product neopeltolide. Journal of the American Chemical Society. 131: 12406-14. PMID 19663512 DOI: 10.1021/Ja904604X |
0.318 |
|
| 2009 |
Leuenroth SJ, Crews CM. Targeting cyst initiation in ADPKD. Journal of the American Society of Nephrology : Jasn. 20: 1-3. PMID 19118147 DOI: 10.1681/Asn.2008101118 |
0.335 |
|
| 2008 |
Corson TW, Aberle N, Crews CM. Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One. Acs Chemical Biology. 3: 677-692. PMID 19112665 DOI: 10.1021/Cb8001792 |
0.675 |
|
| 2008 |
Rodriguez-Gonzalez A, Cyrus K, Salcius M, Kim K, Crews CM, Deshaies RJ, Sakamoto KM. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene. 27: 7201-11. PMID 18794799 DOI: 10.1038/Onc.2008.320 |
0.362 |
|
| 2008 |
Schneekloth AR, Pucheault M, Tae HS, Crews CM. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorganic & Medicinal Chemistry Letters. 18: 5904-8. PMID 18752944 DOI: 10.1016/J.Bmcl.2008.07.114 |
0.796 |
|
| 2008 |
Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chemistry & Biology. 15: 501-12. PMID 18482702 DOI: 10.1016/J.Chembiol.2008.03.020 |
0.334 |
|
| 2008 |
Kim KB, Crews CM. Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors. Journal of Medicinal Chemistry. 51: 2600-5. PMID 18393403 DOI: 10.1021/Jm070421S |
0.412 |
|
| 2008 |
Campbell LJ, Crews CM. Wound epidermis formation and function in urodele amphibian limb regeneration. Cellular and Molecular Life Sciences : Cmls. 65: 73-9. PMID 18030417 DOI: 10.1007/S00018-007-7433-Z |
0.563 |
|
| 2007 |
Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell. 130: 769-74. PMID 17803898 DOI: 10.1016/J.Cell.2007.08.021 |
0.604 |
|
| 2007 |
Petri AF, Schneekloth JS, Mandal AK, Crews CM. Synthesis of the C3-C18 fragment of amphidinolides G and H. Organic Letters. 9: 3001-4. PMID 17616200 DOI: 10.1021/Ol071024E |
0.599 |
|
| 2007 |
Schneekloth JS, Pucheault M, Crews CM. Construction of highly substituted stereodefined dienes by cross-coupling of α-allenic acetates European Journal of Organic Chemistry. 40-43. DOI: 10.1002/Ejoc.200600721 |
0.742 |
|
| 2006 |
Zhang Y, Yeh JR, Mara A, Ju R, Hines JF, Cirone P, Griesbach HL, Schneider I, Slusarski DC, Holley SA, Crews CM. A chemical and genetic approach to the mode of action of fumagillin. Chemistry & Biology. 13: 1001-9. PMID 16984890 DOI: 10.1016/J.Chembiol.2006.07.010 |
0.345 |
|
| 2006 |
Hines J, Roy M, Cheng H, Agapakis CM, Taylor R, Crews CM. Myriaporone 3/4 structure--activity relationship studies define a pharmacophore targeting eukaryotic protein synthesis. Molecular Biosystems. 2: 371-9. PMID 16880957 DOI: 10.1039/B602936A |
0.417 |
|
| 2006 |
Yeh JR, Ju R, Brdlik CM, Zhang W, Zhang Y, Matyskiela ME, Shotwell JD, Crews CM. Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest. Proceedings of the National Academy of Sciences of the United States of America. 103: 10379-84. PMID 16790550 DOI: 10.1073/Pnas.0511313103 |
0.787 |
|
| 2006 |
Schneekloth JS, Sanders JL, Hines J, Crews CM. Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog. Bioorganic & Medicinal Chemistry Letters. 16: 3855-8. PMID 16697191 DOI: 10.1016/J.Bmcl.2006.04.029 |
0.609 |
|
| 2006 |
Mandal AK, Schneekloth JS, Kuramochi K, Crews CM. Synthetic studies on amphidinolide B1. Organic Letters. 8: 427-30. PMID 16435851 DOI: 10.1021/Ol052620G |
0.609 |
|
| 2005 |
Leuenroth SJ, Crews CM. Studies on calcium dependence reveal multiple modes of action for triptolide. Chemistry & Biology. 12: 1259-68. PMID 16356843 DOI: 10.1016/J.Chembiol.2005.09.009 |
0.33 |
|
| 2005 |
Bo Kim K, Fonseca FN, Crews CM. Development and characterization of proteasome inhibitors. Methods in Enzymology. 399: 585-609. PMID 16338383 DOI: 10.1016/S0076-6879(05)99039-3 |
0.308 |
|
| 2005 |
Mandal AK, Schneekloth JS, Crews CM. Stereoselective assembly of a 1,3-diene via coupling between an allenic acetate and a (B)-alkylborane: synthetic studies on amphidinolide B1. Organic Letters. 7: 3645-8. PMID 16092840 DOI: 10.1021/Ol051175M |
0.608 |
|
| 2005 |
Mandal AK, Hines J, Kuramochi K, Crews CM. Developing microcolin A analogs as biological probes. Bioorganic & Medicinal Chemistry Letters. 15: 4043-7. PMID 15993592 DOI: 10.1016/J.Bmcl.2005.06.020 |
0.362 |
|
| 2005 |
Schneekloth JS, Crews CM. Chemical approaches to controlling intracellular protein degradation. Chembiochem : a European Journal of Chemical Biology. 6: 40-6. PMID 15532104 DOI: 10.1002/Cbic.200400274 |
0.689 |
|
| 2004 |
Lin S, Yang ZQ, Kwok BH, Koldobskiy M, Crews CM, Danishefsky SJ. Total synthesis of TMC-95A and -B via a new reaction leading to Z-enamides. Some preliminary findings as to SAR. Journal of the American Chemical Society. 126: 6347-55. PMID 15149232 DOI: 10.1021/Ja049821K |
0.664 |
|
| 2004 |
Schneekloth JS, Fonseca FN, Koldobskiy M, Mandal A, Deshaies R, Sakamoto K, Crews CM. Chemical genetic control of protein levels: selective in vivo targeted degradation. Journal of the American Chemical Society. 126: 3748-54. PMID 15038727 DOI: 10.1021/Ja039025Z |
0.732 |
|
| 2004 |
Brdlik CM, Crews CM. A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases. The Journal of Biological Chemistry. 279: 9475-80. PMID 14676204 DOI: 10.1074/Jbc.M307246200 |
0.795 |
|
| 2003 |
Crews CM, Shotwell JB. Small-molecule inhibitors of the cell cycle: an overview. Progress in Cell Cycle Research. 5: 125-33. PMID 14593706 |
0.323 |
|
| 2003 |
Crews CM. Feeding the machine: mechanisms of proteasome-catalyzed degradation of ubiquitinated proteins. Current Opinion in Chemical Biology. 7: 534-9. PMID 14580555 DOI: 10.1016/J.Cbpa.2003.08.002 |
0.425 |
|
| 2003 |
Sakamoto KM, Kim KB, Verma R, Ransick A, Stein B, Crews CM, Deshaies RJ. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Molecular & Cellular Proteomics : McP. 2: 1350-8. PMID 14525958 DOI: 10.1074/Mcp.T300009-Mcp200 |
0.483 |
|
| 2003 |
Yang ZQ, Kwok BH, Lin S, Koldobskiy MA, Crews CM, Danishefsky SJ. Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity. Chembiochem : a European Journal of Chemical Biology. 4: 508-13. PMID 12794861 DOI: 10.1002/Cbic.200300560 |
0.685 |
|
| 2002 |
Shotwell JB, Koh B, Choi HW, Wood JL, Crews CM. Inhibitors of NF-kappaB signaling: design and synthesis of a biotinylated isopanepoxydone affinity reagent. Bioorganic & Medicinal Chemistry Letters. 12: 3463-6. PMID 12419384 DOI: 10.1016/S0960-894X(02)00769-2 |
0.526 |
|
| 2002 |
Shotwell JB, Krygowski ES, Hines J, Koh B, Huntsman EW, Choi HW, Schneekloth JS, Wood JL, Crews CM. Total synthesis of luminacin D. Organic Letters. 4: 3087-9. PMID 12201723 DOI: 10.1021/Ol026382Q |
0.682 |
|
| 2002 |
Ndubuisil MI, Kwok BH, Vervoort J, Koh BD, Elofsson M, Crews CM. Characterization of a novel mammalian phosphatase having sequence similarity to Schizosaccharomyces pombe PHO2 and Saccharomyces cerevisiae PHO13. Biochemistry. 41: 7841-8. PMID 12056916 DOI: 10.1021/Bi0255064 |
0.683 |
|
| 2001 |
Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chemistry & Biology. 8: 759-66. PMID 11514225 DOI: 10.1016/S1074-5521(01)00049-7 |
0.695 |
|
| 2001 |
Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America. 98: 8554-9. PMID 11438690 DOI: 10.1073/Pnas.141230798 |
0.439 |
|
| 2001 |
Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Medicinal Research Reviews. 21: 245-73. PMID 11410931 DOI: 10.1002/Med.1009 |
0.392 |
|
| 2001 |
Myung J, Kim KB, Lindsten K, Dantuma NP, Crews CM. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Molecular Cell. 7: 411-20. PMID 11239469 DOI: 10.1016/S1097-2765(01)00188-5 |
0.338 |
|
| 2001 |
Princiotta MF, Schubert U, Chen W, Bennink JR, Myung J, Crews CM, Yewdell JW. Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival Proceedings of the National Academy of Sciences of the United States of America. 98: 513-518. DOI: 10.1073/Pnas.98.2.513 |
0.398 |
|
| 2001 |
Sakamoto K, Deshaies R, Crews C. Protechials: A novel approach to pharmacological inhibition of protein function Nature Genetics. 27: 83-83. DOI: 10.1038/87274 |
0.384 |
|
| 2000 |
Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proceedings of the National Academy of Sciences of the United States of America. 97: 12782-7. PMID 11070090 DOI: 10.1073/Pnas.97.23.12782 |
0.313 |
|
| 2000 |
Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim KB, Crews CM, Kraft R, Groettrup M. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. Journal of Immunology (Baltimore, Md. : 1950). 164: 6147-57. PMID 10843664 DOI: 10.4049/Jimmunol.164.12.6147 |
0.364 |
|
| 2000 |
Crews CM, Mohan R. Small-molecule inhibitors of the cell cycle. Current Opinion in Chemical Biology. 4: 47-53. PMID 10679374 DOI: 10.1016/S1367-5931(99)00050-2 |
0.383 |
|
| 2000 |
Shotwell JB, Hu S, Medina E, Abe M, Cole R, Crews CM, Wood JL. Efficient stereoselective syntheses of isopanepoxydone and panepoxydone: A re-assignment of relative configuration Tetrahedron Letters. 41: 9639-9643. DOI: 10.1016/S0040-4039(00)01736-6 |
0.462 |
|
| 1999 |
Kim KB, Myung J, Sin N, Crews CM. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorganic & Medicinal Chemistry Letters. 9: 3335-40. PMID 10612595 DOI: 10.1016/S0960-894X(99)00612-5 |
0.395 |
|
| 1999 |
Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chemistry & Biology. 6: 811-22. PMID 10574782 DOI: 10.1016/S1074-5521(99)80128-8 |
0.356 |
|
| 1999 |
Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Sciences of the United States of America. 96: 10403-8. PMID 10468620 DOI: 10.1073/Pnas.96.18.10403 |
0.766 |
|
| 1999 |
Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BH, Crews CM. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorganic & Medicinal Chemistry Letters. 9: 2283-8. PMID 10465562 DOI: 10.1016/S0960-894X(99)00376-5 |
0.748 |
|
| 1999 |
Meng L, Kwok BH, Sin N, Crews CM. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Research. 59: 2798-801. PMID 10383134 |
0.782 |
|
| 1998 |
Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science (New York, N.Y.). 282: 1324-7. PMID 9812898 DOI: 10.1126/Science.282.5392.1324 |
0.317 |
|
| 1998 |
Sin N, Meng L, Auth H, Crews CM. Eponemycin analogues: syntheses and use as probes of angiogenesis. Bioorganic & Medicinal Chemistry. 6: 1209-17. PMID 9784862 DOI: 10.1016/S0968-0896(98)00089-3 |
0.612 |
|
| 1998 |
Meng L, Sin N, Crews CM. The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase. Biochemistry. 37: 10488-92. PMID 9671519 DOI: 10.1021/Bi9804479 |
0.617 |
|
| 1997 |
Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proceedings of the National Academy of Sciences of the United States of America. 94: 6099-103. PMID 9177176 DOI: 10.1073/Pnas.94.12.6099 |
0.618 |
|
| 1996 |
Crews CM, Lane WS, Schreiber SL. Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proceedings of the National Academy of Sciences of the United States of America. 93: 4316-9. PMID 8633062 DOI: 10.1073/Pnas.93.9.4316 |
0.519 |
|
| 1994 |
Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. The Journal of Biological Chemistry. 269: 15411-4. PMID 8195179 |
0.672 |
|
| 1993 |
Macdonald SG, Crews CM, Wu L, Driller J, Clark R, Erikson RL, McCormick F. Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro. Molecular and Cellular Biology. 13: 6615-20. PMID 8413257 DOI: 10.1128/mcb.13.11.6615-6620.1993 |
0.567 |
|
| 1993 |
Crews CM, Erikson RL. Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell. 74: 215-7. PMID 8343948 DOI: 10.1016/0092-8674(93)90411-I |
0.568 |
|
| 1993 |
Brott BK, Alessandrini A, Largaespada DA, Copeland NG, Jenkins NA, Crews CM, Erikson RL. MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 4: 921-9. PMID 8297798 |
0.488 |
|
| 1993 |
Huang W, Alessandrini A, Crews CM, Erikson RL. Raf-1 forms a stable complex with Mek1 and activates Mek1 by serine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 90: 10947-51. PMID 8248196 DOI: 10.1073/Pnas.90.23.10947 |
0.559 |
|
| 1992 |
Alessandrini A, Crews CM, Erikson RL. Phorbol ester stimulates a protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product. Proceedings of the National Academy of Sciences of the United States of America. 89: 8200-4. PMID 1518847 DOI: 10.1073/Pnas.89.17.8200 |
0.577 |
|
| 1992 |
Crews CM, Alessandrini A, Erikson RL. Erks: their fifteen minutes has arrived. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 3: 135-42. PMID 1504018 |
0.539 |
|
| 1992 |
Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science (New York, N.Y.). 258: 478-80. PMID 1411546 DOI: 10.1126/Science.1411546 |
0.558 |
|
| 1992 |
Crews CM, Erikson RL. Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product. Proceedings of the National Academy of Sciences of the United States of America. 89: 8205-9. PMID 1381507 DOI: 10.1073/Pnas.89.17.8205 |
0.574 |
|
| 1991 |
Crews CM, Alessandrini AA, Erikson RL. Mouse Erk-1 gene product is a serine/threonine protein kinase that has the potential to phosphorylate tyrosine. Proceedings of the National Academy of Sciences of the United States of America. 88: 8845-9. PMID 1717989 DOI: 10.1073/Pnas.88.19.8845 |
0.572 |
|
| 1989 |
Alcorta DA, Crews CM, Sweet LJ, Bankston L, Jones SW, Erikson RL. Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase. Molecular and Cellular Biology. 9: 3850-9. PMID 2779569 DOI: 10.1128/mcb.9.9.3850-3859.1989 |
0.576 |
|
| Show low-probability matches. |
